RBC Capital Maintains Outperform on Intra-Cellular Therapies, Raises Price Target to $79
Portfolio Pulse from richadhand@benzinga.com
RBC Capital analyst Brian Abrahams has maintained an Outperform rating on Intra-Cellular Therapies (NASDAQ:ITCI) and raised the price target from $78 to $79.
August 04, 2023 | 3:51 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital's Outperform rating on Intra-Cellular Therapies is maintained and the price target is raised from $78 to $79.
The news is directly related to Intra-Cellular Therapies and is likely to have a positive impact on its stock price in the short term. The Outperform rating indicates that the analyst expects the company's stock to do better than the market average. The increase in the price target also suggests a positive outlook for the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100